Why PBM transparency rules aren’t enough to lower drug prices
House lawmakers recently passed a health care bill that grabbed headlines for what it excluded: a solution to the looming expiration of enhanced Affordable Care Act tax credits. But largely overlooked inside the bill was a provision that did make it through, a long-requested provision toward creating stronger federal legislation directly targeting pharmacy benefit managers (PBMs), the middlemen who increasingly determine what Americans pay for their medications. These rules …
Why PBM transparency rules aren’t enough to lower drug prices





![Proactive monitoring can prevent emergencies by catching heart signals early [PODCAST]](https://kevinmd.com/wp-content/uploads/unnamed-65-190x100.jpg)






![Politics and fear have replaced science in U.S. pain management [PODCAST]](https://kevinmd.com/wp-content/uploads/11c2db8f-2b20-4a4d-81cc-083ae0f47d6e-190x100.jpeg)






